Company / EPS (Diluted)
ImmunityBio, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.15
FY2025
5-year range
-$1.15 / -$0.43
FY2021-FY2025
Trend
-10.6%
vs FY2024
Sector context
#90 of 204
Health Care
What the data says
At $-1.15, ImmunityBio, Inc.'s eps (diluted) ranks #90 of 204 in the Health Care sector. EPS (Diluted) has declined for 4 consecutive years, from $-0.43 in FY2021 to $-1.15 in FY2025.
Based on SEC 10-K filings.
-1.15 in FY2025.
Declined from $-0.89 to $-1.15 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#90 of 204 in Health CareTop 44% of 204This company -$1.15 Sector average -$0.98
▼
-17.4% below sector average
Key checks
Key Insights
- ImmunityBio, Inc.'s eps (diluted) has declined for 4 consecutive years.
- In FY2025, eps (diluted) decreased 10.6% year-over-year.
- Ranks #90 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.15 | -10.6% |
| FY2024 | -$1.04 | -16.9% |
| FY2023 | -$0.89 | -50.8% |
| FY2022 | -$0.59 | -37.2% |
| FY2021 | -$0.43 | +64.8% |
| FY2020 | -$1.22 | -1.7% |
| FY2019 | -$1.20 | +18.4% |
| FY2018 | -$1.47 | +55.6% |
| FY2017 | -$3.31 | -341.3% |
| FY2016 | -$0.75 | +70.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026